Polymeric human Fc-fusion proteins with modified effector functions

Citations Over TimeTop 12% of 2011 papers

Abstract

The success of Fc-fusion bio-therapeutics has spurred the development of other Fc-fusion products for treating and/or vaccinating against a range of diseases. We describe a method to modulate their function by converting them into well-defined stable polymers. This strategy resulted in cylindrical hexameric structures revealed by tapping mode atomic force microscopy (AFM). Polymeric Fc-fusions were significantly less immunogenic than their dimeric or monomeric counterparts, a result partly owing to their reduced ability to interact with critical Fc-receptors. However, in the absence of the fusion partner, polymeric IgG1-Fc molecules were capable of binding selectively to FcγRs, with significantly increased affinity owing to their increased valency, suggesting that these reagents may prove of immediate utility in the development of well-defined replacements for intravenous immunoglobulin (IVIG) therapy. Overall, these findings establish an effective IgG Fc-fusion based polymeric platform with which the therapeutic and vaccination applications of Fc-fusion immune-complexes can now be explored.

Related Papers

• → The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex(2000)710 cited
• → Crystal Structure of Fcγ Receptor I and Its Implication in High Affinity γ-Immunoglobulin Binding(2011)88 cited
• → Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages(2014)103 cited
• → Fc-Linked IgG N-Glycosylation in FcγR Knock-Out Mice(2020)14 cited
• → Inhibitory Fc-Gamma IIb Receptor Signaling Induced by Multivalent IgG-Fc Is Dependent on Sialylation(2023)5 cited